

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, July 09, 2025 – 12:00 PM – 1:30 PM

Present: Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Venkateswara Davuluri,
Dr. Kolin Good, Dr. John Shand, Grace Robinson (CHC Participant)

Absent: Dr. Chris Squillaro, Dr. Craig Butler

Non-Voting Members: Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Evan Sebastian (Pharmacy),
George Kimbrow (Clinical Policy Coordinator).

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:15 PM.

Next Meeting: Wednesday, October 08, 2025 – 12:00 PM

Submitted By: Shalyn Kline (PHW Pharmacy)

Committee Chair: Shalyn Kline

Date: 10/8/2025

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Jason called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	No new introductions			Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	i. Voting and vote totals ii. Tie breaker iii. Pennsylvania's Review and Approval Process	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q2 2025. No objections were made. Motion to approve: Dr. John Shand Second motion to approve: Jill Schaeffer, RN	Adoption of Q2 2025 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	No old business	No action required or taken.		Shalyn Kline
A. Policy Submission Status	There are 30 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
IV. New Business				

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

A. Provider Education	A vote was taken for the approval of the Hypertonic Saline Use in Cystic Fibrosis provider education. No objections were made. Motion to approve: Dr. John Shand Second motion to approve: Dr. Kolin Good	The provider education was Committee approved.		Shalyn Kline
B. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
C. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 8 new policies created, 38 policies had clinically significant change, 45 policies with no significant changes and 1 policies being replaced/retired for Medicaid. No objections, concerns or comments were made. Motion to approve: Dr. Kolin Good Second motion to approve: Dr. John Shand	The policy revisions were Committee approved.		Shalyn Kline
D. Additional Drug Lists and Policies and Procedures	A vote was taken for the approval of 13 Pharmacy Policy & Procedures Motion to approve: Dr. John Shand Second motion to approve: Jill Schaeffer, RN	The policy and drug lists revisions were Committee approved.		Shalyn Kline
E. Highlights of New Medications/ Significant Changes	Shalyn reviewed the new indication of chronic kidney disease for Furoscix a wearable furosemide pump. Shalyn also reviewed a new formulation of Opdivo-Opdivo Qvantig a SQ formulation injected over 3-5 minutes instead of 30 minutes. Opdivo Qvantig is not indicated for all the same indications as Opdivo and cannot be used in combination with Yervoy.	No action required or taken.		Shalyn Kline
F. Complaints and Grievances Review	Shalyn stated that there was 1 determinations upheld and 4 overturned and 0 withdrawn during pre-grievance. 0 of the 5 determinations were for opioids, 2 were for GLP-1 agonists.	No action required or taken.		Shalyn Kline
G. Drug Utilization Review	Evan presented the drug utilization review, noted the numbers are for March-June.	No action required or taken.		Evan Sebastian

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	FWA – There were 89 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. 5 Participants were identified with three or more practices/hospitals prescribing opioids.			
H. PBM Oversight	Prior Authorization Audits: • April – 95.50% passed • May – 92.86% passed • June – 96.97% passed Call Center: • April – 947 – 100% within TAT • May – 809 – 100% within TAT • June – data not finalized	No action required or taken.		Jason Skaria
I. Open Forum		No action required or taken.		Jason Skaria
J. Next Meeting	Quarter 4 P&T meeting will be held on October 8, 2025.	No action required or taken.		Jason Skaria
Adjournment	The meeting was adjourned at 12:15 pm Jason asked for a motion to adjourn. Motion to adjourn: Jill Schaeffer, RN Second motion to adjourn: Dr. John Shand	Meeting adjourned		Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).